Lack of efficacy is the main reason for the switch.
About one-fifth of patients prescribed an alpha blocker for lower urinary tract symptoms suggestive of benign prostatic hyperplasia have their prescription changed to another alpha blocker, and lack of efficacy is the main reason for the switch, according to a new study published online ahead of print in Urology.
Tae Nam Kim, MD, of Pusan National University Hospital in Pusan, Korea, and colleagues studied 3,200 patients who took 1 of 4 different alpha blockers (doxazosin, alfuzosin, tamsulosin, and silodosin). Of these patients, 694 (21.7%) had a prescription change to another alpha blocker after taking their first one for a mean 10.8 weeks.
Reasons for the change were lack of efficacy (52.7%), adverse events (33.1%), cost (7.0%), inconvenience of taking the drug (4.1%), and cardiovascular morbidity (3.2%).
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.